Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...

Septerna (SEPN), which is developing a treatment for hypoparathyroidism, has proposed terms for an upsized $175M initial ...

Septerna, a nearly three year-old drug developer backed by Goldman Sachs, is aiming for a valuation of up to $628 million as ...

Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...

Septerna Inc. shares rose 19% in their trading debut after the biotechnology company raised $288 million in an enlarged ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Shares of Septerna are set to maker their trading debut Friday after the clinical-stage biotechnology's upsized initial public offering. The South San Francisco company late Thursday said it is ...

Recent health news includes Septerna's market success valued at $970 million, benefits of acupuncture for leg pain, an increase in E. coli infections linked to McDonald's, FDA's approval for a new UTI ...

Septerna is seeking a valuation of $743.1 million in its upsized U.S. initial public offering, the Goldman Sachs-backed drug ...

Septerna, Inc SEPN IPO will take place October, 25 on the NASDAQ exchange under the ticker SEPN. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...